Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Start-Up Developing Precision Antibiotics for Resistant Bacteria

Pseudomonas Aeruginosa bacteria

A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria

Life Science Incubator Gains $100M in Start-Up Funds

Raven in a tree

A new-business accelerator program, begun earlier this year to advance and commercialize biomedical research discoveries from academic labs, is receiving a $100 million founding grant. . . . → Read More: Life Science Incubator Gains $100M in Start-Up Funds

Coalition to Boost African Ancestry Genomic Data

Population genetics

An historically Black medical college and pharmaceutical industry group began a program to increase the numbers of people of African descent in genomic databases. . . . → Read More: Coalition to Boost African Ancestry Genomic Data

Organ Chip Devices to Model for Radiation Sickness

Organ on a chip

The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness. . . . → Read More: Organ Chip Devices to Model for Radiation Sickness

Start-Up Adapts Crispr for Molecular Detection, Raises $40M

Crispr graphic

A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M

Longevity Science Group Spins-Off Biotech Start-Up

Naked mole rat on black background

An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company. . . . → Read More: Longevity Science Group Spins-Off Biotech Start-Up

Collapsed Microbiome Biotech Sells Off Assets

Microbiome illustration

A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program. . . . → Read More: Collapsed Microbiome Biotech Sells Off Assets

Neuro Disease Biotech Gains $61M in Early Funds

Brain cell networks

A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds

Vaccine Shown to Protect Against Multiple Hospital Pathogens

MRSA bacteria

Research with lab mice shows an experimental vaccine stimulates the body’s basic immune system to protect against a range of pathogens associated with hospital infections. . . . → Read More: Vaccine Shown to Protect Against Multiple Hospital Pathogens

Biomanufacturing Company Gains $9.5M in Early Funds

A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round. . . . → Read More: Biomanufacturing Company Gains $9.5M in Early Funds